Patents by Inventor Rachel E. Meyers

Rachel E. Meyers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8252915
    Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 46743, 27417, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 46743, 27417, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 46743, 27417, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: August 28, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, John J. Hunter, Fong-Ying Tsai
  • Publication number: 20110182879
    Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 46743, 27417, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 46743, 27417, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 46743, 27417, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 1, 2010
    Publication date: July 28, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Mark Williamson, Kevin R. Leiby, Rosana Kapeller-Libermann, Peter J. Olandt, Kyle J. MacBeth, Laura A. Rudolph-Owen, Fong-Ying Tsai, John J. Hunter
  • Publication number: 20110150860
    Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 7, 2010
    Publication date: June 23, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rory A.J. Curtis, Thomas Joseph Logan, Maria Alexandra Glucksmann, Rachel E. Meyers, Mark J. Williamson, Laura A. Rudolph-Owen, Miyoung Chun, Fong-Ying Tsai
  • Publication number: 20110092388
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: November 23, 2010
    Publication date: April 21, 2011
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., Board of Regents, The University of Texas system
    Inventors: JAMES LILLIE, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens Hattersley, John E. Monahan, Vickesh Myer, Youzhen Wang, Yong Yao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, JR., Gabriel N. Hortobagyi, Lajos Pusztai
  • Patent number: 7879989
    Abstract: The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 1, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, John J. Hunter
  • Patent number: 7867729
    Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: January 11, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, William J. Cook
  • Publication number: 20100291099
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 17, 2010
    Publication date: November 18, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John Joseph Hunter
  • Patent number: 7799898
    Abstract: The invention provides isolated nucleic acids molecules, designated 33877, 47179, 26886, 46743, 27417, 32252, and 53320 nucleic acid molecules, which encode novel human transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33877, 47179, 26886, 46743, 27417, 32252, or 53320 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33877, 47179, 26886, 46743, 27417, 32252, or 53320 gene has been introduced or disrupted. The invention still further provides isolated 33877, 47179, 26886, 46743, 27417, 32252, or 53320 proteins, fusion proteins, antigenic peptides and anti-33877, 47179, 26886, 46743, 27417, 32252, or 53320 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: September 21, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Rachel E. Meyers
  • Publication number: 20100150901
    Abstract: The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies.
    Type: Application
    Filed: October 22, 2008
    Publication date: June 17, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Kyle J. MacBeth, Rory A.J. Curtis, Laura A. Rudolph-Owen, Nadine S. Weich, Peter J. Olandt, Fong-Ying Tsai, Rosana Kapeller-Libermann, Joseph M. Carroll
  • Patent number: 7732182
    Abstract: The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: June 8, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Mark J. Williamson
  • Publication number: 20100136010
    Abstract: The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 21, 2008
    Publication date: June 3, 2010
    Inventors: Rosana Kappeller-Libermann, David White, Keith E. Robison, Kyle J. MacBeth, Joseph M. Carroll, William James Cook, Rachel E. Meyers, Miyoung Chun, Mark J. Williamson
  • Publication number: 20100105051
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Application
    Filed: September 25, 2009
    Publication date: April 29, 2010
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
    Inventors: JAMES LILLIE, MANJULA GANNAVARAPU, KAREN GLATT, SEBASTIAN HOERSCH, SHUBHANGI KAMATKAR, MAUREEN MERTENS HATTERSLEY, JOHN E. MONAHAN, VICKESH MYER, YOUZHEN WANG, YONG YAO XU, XUMEI ZHAO, RACHEL E. MEYERS, ROBERT C. BAST, JR., GABRIEL N. HORTOBAGYI, LAJOS PUSZTAI
  • Patent number: 7705120
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: April 27, 2010
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, University of Texas System
    Inventors: James Lillie, Manjula Gannavarapu, Karen Glatt, Sebastian Hoersch, Shubhangi Kamatkar, Maureen Mertens, Hattersley, John E. Monahan, Vickesh Myer, Youzhen Wang, Yongyao Xu, Xumei Zhao, Rachel E. Meyers, Robert C. Bast, Jr., Gabriel N. Hortobagyi, Lajos Pusztai
  • Publication number: 20100098713
    Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 15, 2009
    Publication date: April 22, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Joseph M. Carroll, William James Cook, Rosana Kapeller-Libermann, Nadine S. Welch, Rajasekhar Bandaru
  • Patent number: 7696316
    Abstract: The invention provides isolated nucleic acids molecules, designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: April 13, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, John Joseph Hunter, Rachel E. Meyers, Laura A. Rudolph-Owen, Rory A. J. Curtis, Peter J. Olandt, Fong-Ying Tsai, Katherine M. Galvin, Miyoung Chun, Mark J. Williamson, Inmaculada Silos-Santiago, Rajasekhar Bandaru
  • Publication number: 20090324608
    Abstract: The invention provides isolated nucleic acids molecules, designated 53070, 15985, 26583, 21953, m32404, 14089, and 23436 nucleic acid molecules, which encode novel human protein kinase family members, serine/threonine protein kinase family members, serine/threonine phosphatase family members, prolyl oligopeptidase family members, trypsin family members, trypsin serine protease family members, and ubiquitin protease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 53070, 15985, 26583, 21953, m32404, 14089, or 23436 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 53070, 15985, 26583, 21953, m32404, 14089, or 23436 gene has been introduced or disrupted.
    Type: Application
    Filed: September 5, 2007
    Publication date: December 31, 2009
    Inventors: Rachel E. Meyers, Peter J. Olandt, Rosana Kapeller-Libermann, Rory A. J. Curtis, Mark Williamson, Nadine Weich
  • Publication number: 20090280482
    Abstract: The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: December 12, 2007
    Publication date: November 12, 2009
    Inventors: Maria Alexandra Glucksmann, Rosana Kapeller-Libermann, Rachel E. Meyers, Miyoung Chun
  • Patent number: 7611879
    Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 3, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, William James Cook
  • Publication number: 20090269350
    Abstract: The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 20A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: December 16, 2008
    Publication date: October 29, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Mark J. Williamson, Fong-Ying Tsai, Laura A. Rudolph-Owen, Rosanna Kapeller-Libermann, Rachel E. Meyers, Lillian Wei-Ming Chiang, John Joseph Hunter
  • Publication number: 20090263860
    Abstract: The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted.
    Type: Application
    Filed: October 30, 2007
    Publication date: October 22, 2009
    Inventors: Rachel E. Meyers, Mark J. Williamson, Rosana Kapeller-Libermann, Kyle J. MacBeth, John Joseph Hunter, Laura A. Rudolph-Owen, Rajasekhar Bandaru, Fong-Ying Tsai